Reasons for pretreatment attrition and dropout from methylphenidate in adults with attention-deficit/hyperactivity disorder: The role of comorbidities

Journal of Clinical Psychopharmacology

Volumn 29, Issue 6, 2009, Pages 614-616

  Victor, Marcelo M ^a   Grevet, Eugenio H ^a   Salgado, Carlos A I ^a   Silva, Katiane L ^a   Sousa, Nyvia O ^a   Karam, Rafael G ^a   Vitola, Eduardo S ^a   Picon, Felipe A ^a   Zeni, Gregory D ^a   Contini, Veronica ^b   Rohde, Luis A P ^b   Belmonte De Abreu, Paulo ^a,b   Bau, Claiton H D ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ABSENTEEISM; AGEISM; AGORAPHOBIA; ALCOHOL ABUSE; ALCOHOLISM; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RELEASE; DYSTHYMIA; GENERALIZED ANXIETY DISORDER; HUMAN; INTERVIEW; LETTER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPATHY; SCHEDULE FOR AFFECTIVE DISORDERS AND SCHIZOPHRENIA; SEX DIFFERENCE; SOCIAL PHOBIA; SOCIAL STATUS; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUBSTANCE ABUSE; TREATMENT REFUSAL; TREATMENT WITHDRAWAL;

AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMORBIDITY; HUMANS; METHYLPHENIDATE; PATIENT COMPLIANCE; PATIENT DROPOUTS;

EID: 72949112761     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181c00b1e     Document Type: Letter

References (31)

1. Bockting CL, ten Doesschate MC, Spijker J, et al. Continuation and maintenance use of AD in recurrent depression. Psychother Psychosom. 2008;77:17-26.
2. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry. 1998;59:279-288.
3. Phelps JR. Agitated dysphoria after late-onset loss of response to AD: a case report. J Affect Disord. 2005;86:277-280.
4. El-Mallakh RS, Karippot A. Antidepressant-associated chronic irritable dysphoria (ACID) in bipolar disorder: a case series. J Affect Disord. 2005;84:267-272.
5. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, IV. Psychiatr Clin North Am. 1999;22:517-534.
6. El-Mallakh RS, Waltrip C, Peters C. Can long-term antidepressant use be depressogenic? J Clin Psychiatry. 1999; 60:263-264.
7. Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry. 2003;64: 123-133.
8. Kirkpatrick B, Alphs L, Buchanan RW. The concept of supersensitivity psychosis. J Nerv Ment Dis. 1992;180:265-270.
9. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27:159-169.
10. Factor SA. Levodopa. In: Pahwa R, Lyons KE, eds. Handbook Disease. 4th ed. New York, NY: Informa Healthcare USA, Inc; 2007:309-334.
11. Repetto M, Gold MS. Cocaine and crack: neurobiology. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance Abuse. A Comprehensive Textbook. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:195-217.
12. Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:435-451.
13. D'Aquila PS, Peana AT, Tanda O, et al. Carbamazepine prevents imipramine-induced behavioural sensitization to the dopamine D(2)-like receptor agonist quinpirole. Eur J Pharmacol. 2001;416:107-111.
14. Olfson M, Marcus SC, Zhang HF, et al. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder. J Manag Care Pharm. 2007; 13:570-577.
15. Centorrino F, Hernan MA, Drago-Ferrante G, et al. Factors associated with noncompliance with psychiatric outpatient visits. Psychiatr Serv. 2001;52:378-380.
16. Issakidis C, Andrews G. Pretreatment attrition and dropout in an outpatient clinic for anxiety disorders. Acta Psychiatr Scand. 2004;109:426-433.
17. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:456-463.
18. Bouffard R, Hechtman L, Minde K, et al. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry. 2003;48:546-554.
19. Kooij JJ, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med. 2004;34:973-982.
20. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/ hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68:268-277.
21. Reimherr FW, Willians ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007;68:93-101.
22. Grevet EH, Bau CH, Salgado CA, et al. Interrater reliability for diagnosis in adults of attention deficit hyperactivity disorder and oppositional defiant disorder using K-SADS-E. Arq Neuropsiquiatr. 2005;63: 307-310.
23. Grevet EH, Bau CH, Salgado CA, et al. Lack of gender effects on subtype outcomes in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2006;256:311-319.
24. Karam RG, Bau CH, Salgado CA, et al. Late-onset ADHD in adults: milder, but still dysfunctional. J Psychiatr Res. 2009;43: 697-670.
25. Mercadante MT, Asbahar F, Rosário MC, et al. K-SADS, entrevista semi-estruturada para diagnóstico em psiquiatria da infância, versão epidemiológica. São Paulo, Brazil: FMUSP; 1995.
26. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I DisordersVPatient Edition (SCID-I/P, Version 2.0, 8/98 Revision). New York, NY: Biometrics Research Department, New York Psychiatry Institute; 1998.
27. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The MiniYInternational Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22-33.
28. Brown C, Schulberg HC, Shear MK. Phenomenology and severity of major depression and comorbid lifetime anxiety disorders in primary medical care practice. Anxiety. 1996;2:210-218. (Pubitemid 126812830)
29. Li X, Sun H, Purl A, et al. Factors associated with pretreatment and treatment dropouts among clients admitted to medical withdrawal management. J Addict Dis. 2007;26:77-85.
30. Souery D, Oswald P, Massat I, et al. Group for the Study of Resistant Depression. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68:1062-1070.
31. Keller MB. Prevalence and impact of comorbid anxiety and bipolar disorder. J Clin Psychiatry. 2006;67:5-7.